Serum IL-8 and IL-12 levels in breast cancer.
Interleukins (ILs) are known to play a fundamental role in cancer. We investigated the serum levels of IL-8 and IL-12, in breast cancer patients, and their relationship with the prognostic parameters and therapy. Forty eight patients with pathologically verified breast carcinoma and 21 healthy controls were enrolled into the study. Serum samples were obtained at baseline and after two cycles of chemotherapy. Serum IL-8 and IL-12 levels were determined using enzyme-linked immunosorbent assay (ELISA). There was no significant difference in the baseline serum IL-8 and IL-12 levels between breast cancer patients and healthy controls (p = 0.365 and p = 0.871, respectively), no significant correlation between the prognostic parameters and the serum IL-8, IL-12 levels. However, in the subgroup consisting of metastatic breast cancer patients, baseline serum IL-8 levels were significantly higher compared with non-metastatic disease (p = 0.047). Anthracycline-based chemotherapy and the addition of taxane did not change the levels of both serum IL-8 and IL-12. Serum IL-8 level may be useful in determining metastatic breast cancer. Larger studies are needed to confirm this finding.
Derin
Duygu
D
Institute Of Oncology, Istanbul University, Istanbul, Turkey. dygderin@yahoo.com
Soydinc
Hilal Oguz
HO
Guney
Nese
N
Tas
Faruk
F
Camlica
Hakan
H
Duranyildiz
Derya
D
Yasasever
Vildan
V
Topuz
Erkan
E
D000328:Adult; D000368:Aged; D001943:Breast Neoplasms / Q000097:blood / Q000175:diagnosis* / Q000188:drug therapy; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D018664:Interleukin-12 / Q000097:blood*; D016209:Interleukin-8 / Q000097:blood*; D008875:Middle Aged; D011379:Prognosis
D016209:Interleukin-8; D018664:Interleukin-12